

Supplementary Material

***Calculus Bovis Sativus* Improves Bile Acid Homeostasis via Farnesoid X Receptor-Mediated Signaling in Rats with Estrogen-Induced Cholestasis**

Dong Xiang¹, Jinyu Yang¹, Yanan Liu¹, Wenxi He¹, Si Zhang¹, Xiping Li¹, Chenliang Zhang^{1*}, Dong Liu^{1*}

*** Correspondence:**

Dong Liu, MD.


E-mail address: ld2069@outlook.com

Chenliang Zhang, MD.


E-mail address: clzhang@tjh.tjmu.edu.cn

1 Supplementary Figures and Tables


1.1 Supplementary Figures




Supplementary Figure 1. Immunohistochemical positive staining cells of CK19 in non-cholestatic or cholestatic rats after vehicle or CBS administration. Positive staining cells were quantified by counting three different fields in each section. Data are presented as the mean \pm SD (n=6). Significant differences compared with non-cholestatic group, **p<0.01, compared to 17 α -ethinylestradiol (EE) group, ##p<0.01.




Supplementary Figure 2. Representative LC-MS/MS chromatogram of bile acids in liver. (A) Unconjugated bile acids and (B) conjugated bile acids. Abbreviations: MCA, muricholic acid; CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; TMCA, tauromuricholic acid; TCA, taurocholic acid; TDCA, taurodeoxycholic acid; TUDCA, tauroursodeoxycholic acid.



Supplementary Figure 3. Immunohistochemical positive staining area of hepatic CYP7A1 in non-cholestatic or cholestatic rats after vehicle or CBS administration. Positive staining was quantified by counting three different fields in each section. Data are presented as the mean ± SD (n=6). Significant differences compared with non-cholestatic group, *p<0.05, compared to 17 α -ethinylestradiol (EE) group, #p<0.05.



Supplementary Figure 4. Gene expressions of hepatic nuclear receptors Fxr, Pxr, Car, Vdr, Lxr and Ppara analyzed by DNA microarray. Data are presented as the mean ± SD (n=3). Significant differences compared with non-cholestatic group, **p<0.01.



Supplementary Figure 5. Immunohistochemical positive staining area of hepatic FXR and intestinal FXR in non-cholestatic or cholestatic rats after vehicle or CBS administration. Positive staining was quantified by counting three different fields in each section. Data are presented as the mean \pm SD (n=3). Significant differences compared with non-cholestatic group, **p<0.01, compared to 17 α -ethinylestradiol (EE) group, #p<0.05; ##p<0.01.

1.2 Supplementary tables

Supplementary Table 1 The primer sequences used for real-time PCR assay in rats

Gene	Accession NO.	Protein	Forward primer (5' →3')	Reverse primer (5' →3')	Product length
<i>Slc10a1</i>	NM_017047.1	NTCP	TGCACCATAGGGATCGTCCTC	GATGCTGTTGCCACATTGA	135
<i>Slco1a1</i>	NM_017111.1	OATP1A1	TGGGGAAGGTTGCTGGCCCAATTT	GGTGGTTAATCCAGCAACTGCTGC	659
<i>Abcc3</i>	NM_080581.1	MRP3	TCCCCTTCTCGGAGACAGTAAC	CTTAGCATCACTGAGGACCTTGAA	87
<i>Abcc4</i>	NM_133411.1	MRP4	GAAGGAAAATGAGGAAGCAGAG	GGATGACTGTTGAGACCAAATC	100
<i>Slco1b2</i>	NM_001270587.1	OATP1B2	AGACGTTCCCATCACAAACCAC	GCCTCTGCAGCTTTCCTTGA	68
<i>Abcc2</i>	NM_012833.2	MRP2	CTCGGTCTTATGCGGCGTATTC	CCGTGACTGATGGAGTTTGTGTT	179
<i>Abcb11</i>	NM_031760.1	BSEP	CGTGCTTGTTGGAAGAAGTTG	GGGAGTAGATGGGTGTGACTG	131
<i>Abcb4</i>	NM_012690.2	MDR2	CTGTAGCGGGAATTGTTG	GATGCCGTAGATGTGAGC	215
<i>Cyp7a1</i>	NM_012942.2	CYP7A1	GTCCGGATATTCAAGGATGC	GGGAATGCCATTTACTTGGGA	107
<i>Cyp8b1</i>	NM_031241.1	CYP8B1	ATGAAGGCTGTGCGAGAG	TCTCTTCATCACGCTGTC	127
<i>Cyp3a2</i>	NM_153312.2	CYP3A2	TGACTGCTCTTGATGCATGGTT	ATCACAGACCTTGCCAACTCCT	104
<i>Cyp2b10</i>	XM_017594657.1	CYP2B10	GGTGGAGGAACTGCGGAAAT	TGATGACTGGAAGAGGAAGGT	65
<i>Sult2a1</i>	NM_131903.1	SULT2A1	AGGAACGAACTGGCTGATTG	ATGGGAAGATGGGAGGTCAT	171
<i>Slc27a5</i>	NM_024143.2	BAL	TGCCCTTGCTACACTCTG	TGGTCCCTGAAGTATAGATG	264
<i>Baat</i>	NM_017300.2	BAAT	CTGTGCAACTACGGTTTTGGCGAA	TCAGGCCTGTGACCCGGATA	136
<i>Nr1h4</i>	NM_021745.1	FXR	TGAGCGTCTACAGCGAAAGTG	GGGATGGTGGTCTTCAAATAAG	121
<i>Nr1i3</i>	XM_017598932.1	CAR	ACCAGTTGTGCAGTTCAGG	CTTGAGAAGGGAGATCTGGT	197
<i>Nr1i2</i>	NM_052980.2	PXR	GACGGCAGCATCTGGAACCTAC	TGATGACGCCCTTGAACATG	112
<i>Nr1i1</i>	NM_017058.1	VDR	GCCCCTATAAAGTTCAGGTG	GGATAGCGGTCCTGAATGG	148
<i>Nr1h3</i>	XM_006234534.2	LXR	TCAGCATCTTCTCTGCAGACCGG	TCATTAGCATCCGTGGGAACA	144
<i>Ppara</i>	XM_017594681.1	PPARA	CGGGTCATACTCGCAGGAAAG	TGGCAGCAGTGAAGAATCG	155
<i>Nr0b2</i>	NM_057133.1	SHP	CTCGGTTTGCATACAGTGTGTTGAC	GCATATTGGCCTGGAGGTTTT	75
<i>Fgf15</i>	NM_130753	FGF15	ACGGGCTGATTCGCTACTC	TGTAGCCCAAACAGTCCATTTCT	66

Supplementary Table 2 linear regression, correlation coefficient, and linearity range of the bile acid determination

Bile acids	Linear regression equation($1/x^2$)	Correlation coefficient	linearity range ($\mu\text{mol/L}$)
TCA	$y=0.548x-0.0108$	$r=0.9951$	0.275-100.0
DCA	$y=6.6x+0.471$	$r=0.9972$	0.275-100.0
TDCA	$y=0.707x-0.0131$	$r=0.9978$	0.275-100.0
T-MCA	$y=0.57x-0.00806$	$r=0.9954$	0.275-100.0
MCA	$y=8.25x-0.00303$	$r=0.9986$	0.0069-10.00
CA	$y=7.96x+0.000283$	$r=0.9974$	0.0069-10.00
CDCA	$y=5.92x-0.00455$	$r=0.9982$	0.0069-10.00
TUDCA	$y=0.714x+0.000566$	$r=0.9974$	0.0069-10.00

Abbreviations: MCA, muricholic acid; CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; TMCA, tauromuricholic acid; TCA, taurocholic acid; TDCA, taurodeoxycholic acid; TUDCA, tauroursodeoxycholic acid.

Supplementary Table 3 Summary of intra-day accuracy, inter-day accuracy, precision, and recovery of the bile acid determination

Bile acid	Quality control	Concentration ($\mu\text{mol/L}$)	Intra-day(n=5)		Inter-day(n=5)		Recovery (%)
			Accuracy (%)	RSD(%)	Accuracy (%)	RSD(%)	
TCA	LQC	11.1	102.6	8.6	98.4	4.3	89.6
	MQC	50.0	90.3	4.3	91.4	3.1	87.4
	HQC	80.0	96.5	9.1	94.3	5.9	97.5
DCA	LQC	11.1	103.6	6.3	97.5	5.8	91.1
	MQC	50.0	94.2	2.1	96.3	2.4	95.3
	HQC	80.0	89.3	8.7	91.5	6.3	94.2
TDCA	LQC	11.1	98.4	11.6	94.2	5.6	100.3
	MQC	50.0	101.2	8.9	99.4	4.9	96.4
	HQC	80.0	91.1	3.7	93.5	8.5	97.6
TMCA	LQC	11.1	93.6	9.4	97.1	2.9	91.2
	MQC	50.0	98.1	13.4	97.2	7.4	97.3
	HQC	80.0	91.7	11.3	89.4	4.8	92.7
MCA	LQC	1.11	89.5	9.4	93.5	10.6	89.6
	MQC	5.00	97.3	5.6	95.4	6.7	91.9
	HQC	8.00	96.2	7.3	94.7	4.1	98.2
CA	LQC	1.11	95.4	4.0	97.1	5.4	90.4
	MQC	5.00	97.2	8.3	95.0	5.3	93.3
	HQC	8.00	91.3	12.6	90.9	8.9	88.7
CDCA	LQC	1.11	94.1	2.9	97.2	7.4	95.7
	MQC	5.00	99.3	8.9	98.5	8.1	92.1
	HQC	8.00	100.1	4.3	102.5	5.4	90.6
TUDCA	LQC	1.11	92.4	5.9	89.1	8.9	98.9
	MQC	5.00	94.8	8.3	91.7	7.3	100.8
	HQC	8.00	88.3	7.8	92.6	4.4	101.6

Abbreviations: LQC, low quality control; MQC, middle quality control; HQC, high quality control.

Supplementary Table 4 Gene ontology analysis of differentially expressed genes of non-cholestatic, 17 α -ethinylestradiol (EE) and EE+*Calculus Bovis Sativus* (CBS) groups

Category	Term	Count	-lg(PValue)	Genes
BP	GO:0042493~response to drug	10	3.18	ECE1, MVD, NPPC, FZD1, COL1A1, AK4, CALR, AOC1, PFAS, NNMT
BP	GO:1903298~negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway	2	1.74	NOL3, PINK1
BP	GO:0000122~negative regulation of transcription from RNA polymerase II promoter	9	1.69	CEBPA, TSC22D3, THRB, TBX3, HNRNPA2B1, PER1, CALR, CELA1, NFIB
BP	GO:0050821~protein stabilization	4	1.67	ATP1B1, PINK1, CCT6A, CALR
BP	GO:0060662~salivary gland cavitation	2	1.57	TGM2, NFIB
CC	GO:0070062~extracellular exosome	26	3.62	ATP1B1, THRB, POLG, HNRNPA2B1, IGFALS, PDIA6, PPCS, TFG, CCT6A, AK4, CALR, RPS2, PFAS, PTER, ACTG1, APP, ECE1, GSTK1, PTP4A1, TGFBI, TGM2, VNN1, RGD1309534, SCARB1, LAMC1, AOC1
CC	GO:0031012~extracellular matrix	6	2.20	TGFBI, TGM2, COL1A1, CCT6A, LAMC1, CALR
CC	GO:0005790~smooth endoplasmic reticulum	3	2.11	APP, PDIA6, CALR
CC	GO:0005925~focal adhesion	7	2.01	ACTG1, FZD1, TGM2, ZYX, CALR, PALLD, RPS2
CC	GO:0005794~Golgi apparatus	10	1.87	SLC39A14, APP, BLZF1, ING2, CABP2, SGPP1, COL1A1, CALR, TRIP11, CALU
MF	GO:0005515~protein binding	17	2.66	CEBPA, NOL3, MAFB, HNRNPA2B1, FZD1, CCNL1, PINK1, PDIA6, CCT6A, CALR, APP, BLZF1, CAPN10, TGM2, PER1, COL1A1, ERFFI1
MF	GO:0019900~kinase binding	4	2.06	CEBPA, NOL3, PER1, ERFFI1
MF	GO:0042803~protein homodimerization activity	10	1.93	CEBPA, CHKA, ECE1, MASP1, THRB, MVD, NPPC, FZD1, SCARB1, AOC1
MF	GO:0005506~iron ion binding	5	1.84	CYP2B2, CYP2B15, CALR, CYP8B1, PHF8
MF	GO:0004305~ethanolamine kinase activity	2	1.74	CHKA, ETNK1

Abbreviations: BP-biological process; CC-cellular component; MF-molecular function.

Supplementary Table 5 Pathways analysis of differentially expressed genes of non-cholestatic, 17 α -ethinylestradiol (EE) and EE+*Calculus Bovis Sativus* (CBS) groups.

Term	Count	-lg(PValue)	Genes
Metabolic pathways	15	2.323349	CHKA, CYP2B2, HYKK, MVD, POLG, NDUFA6, PPCS, ETNK1, CYP2B15, AK4, CYP8B1, AOC1, PFAS, SLC27A5, NNMT
Bile secretion	4	2.217689	ATP1B1, ABCC3, SCARB1, SLC27A5
Primary bile acid biosynthesis	2	1.090755	CYP8B1, SLC27A5
Chemical carcinogenesis	3	1.08231	CYP2B2, GSTK1, CYP2B15
Phagosome	4	1.077844	ACTG1, SCARB1, CALR, CD209B
Pantothenate and CoA biosynthesis	2	1.019434	VNN1, PPCS
Focal adhesion	4	1.009053	ACTG1, COL1A1, ZYX, LAMC1